S 5002 United States Senate · 117th Congress

FDA Modernization Act 2.0

Summary

FDA Modernization Act 2.0 This bill authorizes the use of certain alternatives to animal testing, including cell-based assays and computer models, to obtain an exemption from the Food and Drug Administration to investigate the safety and effectiveness of a drug. The bill also removes a requirement to use animal studies as part of the process to obtain a license for a biological product that is biosimilar or interchangeable with another biological product.

Issues: ✓ Technology

Bill status passed 3 of 5 stages cleared

Introduction

Sep 2022

Committee Review

Senate Passage

Sep 2022

House Passage

President

Introduced Sep 29, 2022 Last action Sep 29, 2022

Floor votes

How they voted

This bill passed the Senate by voice vote (no roll call recorded).

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Sep 29, 2022

Introduced

Introduced in the Senate, read twice, considered, read the third time, and passed without amendment by Unanimous Consent. (consideration: CR S5514-5515; text: CR S5514-5515)

upper

Sep 29, 2022

Upper · Passed

Passed/agreed to in Senate: Introduced in the Senate, read twice, considered, read the third time, and passed without amendment by Unanimous Consent.

upper

Sep 29, 2022

Introduced

Introduced in Senate

upper

1 primary · 11 co-sponsors